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ABSTRACT 
Objectives: To study were to formulate the ethanolic extract of Cryptolepis sanguinolenta root into tablets and to evaluate the effect of different 
binders and binder concentration on the properties of tablets.  
Materials and method: The phytochemistry of ethanolic extract of Cryptolepis sanguinolenta was evaluated. The tablets were formulated by wet 
granulation using gelatin and sodium carboxymethyl cellulose (SCMC) as binders at concentrations of 2 %, 4 %, 6 % and 8 %w/w. The tablets were 
evaluated using the necessary official and unofficial tests.  
Results: Phytochemical analysis revealed the presence of alkaloids, terpenoids, steroids, proteins, carbohydrate, resins, reducing sugars and 
glycosides. Tannins, saponins, flavonoids and acidic compounds were absent. The tablets passed the uniformity of weight test and deviations 
obtained complied with BP specifications. Tablets disintegration time ranged from 8.00 ± 0.10 to 13.50 ± 0.21 min for tablets formulated with 2 and 
4 % gelatin and 10.00 ± 0.17 to 31.00 ± 0.27 min for tablets formulated with 2 and 8 % SCMC. C. sanguinolenta tablets formulated gelatin 
significantly showed higher hardness values than SCMC (p < 0.05). Tablets showed friability of approximately ≤ 1 %.  
Conclusion: Therefore, gelatin showed good properties for formulating Cryptolepis sanguinolenta normal release tablets than SCMC. 
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INTRODUCTION 
Cryptolepis sanguinolenta is a thin-stemmed twining and scrambling 
shrub up to 8 m long, containing yellow-orange juice which becomes 
red upon drying. It is a member of the family Apocynaceae 
(subfamily: Periplocoideae). The plant is native to West Africa and is 
found in countries like Ghana, Nigeria, Cote d'Ivoire, Guinea, Guinea-
Bissau, Mali, Senegal, Sierra Leone, Angola, Congo, Uganda, and 
Cameroon [1]. It is a medicinal plant used by some traditional 
herbalist in the treatment of fever, urinary, and upper respiratory 
tract infections [1]. The use of this plant as a medical therapy has 
increased as it has been proposed that the root and leave extracts 
have hypotensive, antipyretic, anti-inflammatory, antidiarrhoeal, in 
vitro antibacterial and antimalarial effects [2]. It is commonly called 
nibima, Kadze, gangamauo, or yellow-die root. It is called paran pupa 
in the Yoruba- speaking areas of Nigeria [1]. Studies have 
documented the antidiabetic potentials of Cryptolepis sanguinolenta 
[3-5]. Crude extracts of C. sanguinolenta and their fractions, as well as 
indoquinoline alkaloids isolated from the plant, have been shown to 
have activity against Plasmodium falciparum both in vitro and in vivo 
[6-8]. In addition to studies indicating anti-plasmodial effect, extracts 
of C. sanguinolenta have been shown to have anti-microbial [9-10], and 
anti-inflammatory activities [6]. Extracts from various morphological 
parts of Cryptolepis sanguinolenta are widely used traditionally in 
folklore medicine in many parts of the world for the management, 
control, and treatment of diabetes mellitus. The hypoglycemic 
activity of Cryptolepis sanguinolenta is associated with its influence 
to reduce intestinal glucose absorption and transport [6]. 
The primary benefit of using plant-derived medicine is that they are 
relatively safer than synthetic alternatives, offering profound 
therapeutic benefits and more affordable treatments [11]. In recent 
times, focus on plant research has increased all over the world and a 
lot of evidence has been collected to show immense potential of 
medicinal plants used in various traditional systems [12]. Plants may 
become the bases for the development of a new medicine or they 
may be used as phyto-medicine for the treatment of disease [13]. It is 
estimated that today, plant materials are present in, or have 
provided the models for 50 % Western drugs [14]. Plant derived drug 
serve as a prototype to develop more effective and less toxic 
medicine [15]. Plants with anti malarial, antihelmintic, antidiabetic 
and anti-inflammatory properties have been of immense 
ethnomedicinal use to mankind. In view of the widespread use of 
herbal products, important technical aspects such as standardization 
and quality control will be of immense benefit in order to enhance 
their efficacy and improve patient’s compliance [16]. 
Tablet dosage forms are the most popular and preferred drug 
delivery systems in terms of precision of unit dose, low cost, patient 
compliance, and good physical and chemical stability and account for 
70 % - 80 % of all pharmaceutical dosage forms [17]. Tablets have 
remained the most common dosage form by which medicaments are 
usually administered to patients because of their advantages over 
the other dosage forms [18]. Therefore the objective of this work is to 
formulate the methanolic extract of Cryptolepis sanguinolenta into 
tablets and to study the effect of different binders and binder 
concentration on the in vitro properties of the tablets. 
MATERIALS AND METHODS 
Lactose (Merck, Germany), maize starch, sodium carboxymethyl 
cellulose, gelatin, ethanol (BDH, England), magnesium stearate (May 
and Baker, England), distilled water (Lion water, Nsukka, Nigeria). 
Cryptolepis sanguinolenta root extract was obtained from a batch 
processed in our laboratory. All other reagents and solvents were 
analytical grade and were used as supplied. 
Collection and authentication of plant material 
Cryptolepis sanguinolenta roots were collected from the Army 
Barrack’s field along Edem road Nsukka, Enugu State, Nigeria in the 
month of June, 2011. The plant material was authenticated by Mr. 
A.O. Ozioko, a consultant taxonomist with the International Center 
for Ethnomedicine and Drug Discovery (InterCEDD) Nsukka. The 
voucher specimen of the plant was deposited in the herbarium of the 
Department of Pharmacognosy and Environmental Medicines, 
University of Nigeria, Nsukka. 
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Preparation of plant extract for phytochemical analysis 
 
Cryptolepis sanguinolenta roots were washed thoroughly in water, 
chopped into tiny pieces then dried in an air-circulating oven in the 
laboratory at 35 – 40oC. The dried roots were milled severally in an 
equipment of hammer mill type. The powdered roots (210 g) were 
extracted by maceration with 95 % ethanol for 48 h. The extract was 
filtered and concentrated to dryness using a rotary evaporator 
attached to a vacuum pump to obtain the crude powdered extract 
(10 g) which was stored at a temperature of 40oC until use. 
 
Phytochemical Screening 
Phytochemical tests were carried out on the powdered extract for 
the presence of alkaloids, tannins, saponins, flavonoids, resins, fats 
and oils, steroids, glycosides, terpenoids, acidic compounds, 
carbohydrates, reducing sugars and proteins. The tests were carried 
out using standard procedures of analysis [18-20]. 
Preparation of granules 
Granules were prepared by wet granulation method using two 
different binders at concentrations of 2 %, 4 %, 6 % and 8 %w/w. 
Details of granulation are given in Table I. Lactose was used as the 
filler and maize starch BP as disintegrant (10 % w/w) were dried 
and mixed for 10 min in a tumbler mixer with the crude extract of 
Cryptolepis sanguinolenta. The powder mixtures were moistened 
with the appropriate amount of binder solution. The homogeneous 
wet mass was then screened through a 1.7 mm sieve and the wet 
granules dried in a hot air oven at 55°C for 1 h. Thereafter, the dried 
granules were screened through a 1.0 mm sieve. 
 
Table 1: Composition of Cryptolepis sanguinolenta tablet 
Batch 
 
C. sanguinolenta extract 
(mg) 




Lactose qs (mg) 
F1 
 
5.0 6.0 - 
 
 15.0 3.0 300.0 
F2 
 
5.0 12.0 -  15.0 3.0 300.0 
G1 
 
5.0 - 6.0  15.0 3.0 300.0 
G2 
 
5.0 - 12.0  15.0 3.0 300.0 
G3 
 
5.0 - 18.0  15.0 3.0 300.0 
G4 
 
5.0 - 24.0  15.0 3.0 300.0 
Key: F1 and F2 contain 2 and 4 %w/w gelatin, G1 – G4 contain 2, 4, 6, and 8 %w/w SCMC, SCMC: sodium carboxymethyl cellulose.
  
Preparation of tablets 
Initially granules were treated with lubricant i.e. magnesium 
stearate. Tablets were prepared by compressing the lubricated 
granules at 46-48 kgf using a 9.0 mm punch and die set fitted into an 
automated F3 Manesty Single Punch tabletting machine. 
EVALUATION OF TABLETS 
Disintegration time test 
Disintegration time test was conducted using an Erweka ZT 120 
basket and rack assembly and 0.1 N HCl maintained at 37.0 ± 1.0 oC 
as the disintegration medium. Ten tablets from each batch were 
used for the test and the procedure being as stipulated in the BP, 
2009 for normal release tablets [21]. 
Uniformity of Weight  
Twenty tablets were randomly selected from each batch. The tablets 
were weighed individually using an electronic balance (Ohaus 
Adventurer, China) and the individual weights recorded. The mean 
weight, standard deviation and percentage deviation were 
calculated [21]. 
Tablet friability test  
Twenty tablets were randomly selected from each batch of the 
tablet. The tablets were dedusted and weighed. The tablets were 
placed into the drum of the friabilator (Erweka GmbH, Germany) 
and rotated at 25 rpm for 4 min. The tablets were removed from the 
friabilator, dedusted and reweighed. The friability result was 
expressed as loss of mass expressed as a percentage of the initial 





 ]                (1) 
where Wo and W are the initial weight and final weight of the tablets 
respectively.  
 
Hardness/Crushing Strength Test 
This test was carried out using a Monsanto-stokes hardness tester. 
Ten tablets from each batch were randomly selected. Each tablet 
was placed between the jaws of the hardness tester and force was 
applied by adjusting the knob of tester until the tablet integrity 
failed. The results were recorded in kgf. 
Statistical analysis 
Statistical analysis was carried out using SPSS version 14.0 (SPSS 
Inc. Chicago, IL.USA). All values are expressed as mean ± SD. Data 
were analysed by one-way analysis of variance (ANOVA). 
Differences between means were assessed by a two-tailed student’s 
T-test. P < 0.05 was considered statistically significant.  
RESULTS 
Phytochemical constituents of C. sanguinolenta root extract  
Results of phytochemical screening of Cryptolepis sanguinolenta root 
extract are shown in Table 2. The results indicated the presence of 
very important phytochemicals. Phytochemical analysis of 
Cryptolepis sanguinolenta root revealed the presence of alkaloids, 
terpenoids, steroids, proteins, carbohydrate, resins, reducing sugars 
and glycosides in substantial quantities. Tannins, saponins, 
flavonoids and acidic compounds were however, not found in the 
plant root.  
TABLET PROPERTIES 
Weight uniformity 
The results of tablets weight uniformity test presented in Table 3 
showed that weights of C. sanguinolenta tablets ranged from 310.95 
± 2.42 to 311.15 ± 1.76 mg for batches F1 and F2 formulated with 2 
and 4 % gelatin, 294.55 ± 1.65 to 303.90 ± 2.60 mg for tablets G1 and 
G2 formulated with 2 and 4 % SCMC. The low coefficient of variation 
exhibited by these formulations confirmed the reproducibility of 
these formulations and the reliability of the production process.  
Disintegration time  
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The results of the disintegration time of C. sanguinolenta tablets are 
shown in Table 3. From the results, the tablets exhibited 
disintegration time range of 8.00 ± 0.10 to 13.50 ± 0.21 min for F1 
and F2 tablets formulated with 2 and 4 % gelatin and 10.00 ± 0.17 to 
31.00 ± 0.27 min for tablets formulated with 2 and 8 % SCMC (G1 
and G4). 
Tablets hardness 
The results of tablets hardness are shown in Table 3. From the 
results, C. sanguinolenta tablets exhibited hardness that ranged from 
4.76 ± 0.05 to 5.80 ± 0.07 kgf for F1 and F2 tablets formulated with 2 
and 4 % gelatin and 2.00 ± 0.03 to 5.00 ± 0.07 kgf for tablets 
formulated with 2 and 8 % SCMC (G1 and G4). Generally, tablets 
formulated with gelatin showed higher hardness values than SCMC. 
Tablets friability  
The results of tablets friability test shown in Table 3 showed that 
tablets friability ranged from 0.84 to 1.28 % for F1 and F2 tablets 
formulated with 2 and 4 % gelatin and 0.92 to 1.31 % for tablets 
formulated with 8 and 4 % SCMC (G4 and G2). Friability test 
measures the resistance of the tablets to abrasion. 
DISCUSSIONS 
Phytochemical constituents of C. sanguinolenta root extract  
The presence of alkaloids in high concentration in the plant root 
explains the traditional use of the plant for the treatment of malaria. 
The medicinal plants that are moderately rich in alkaloids have 
potential health promoting effects [22]. Crude extracts of C. 
sanguinolenta and their fractions, as well as indoquinoline alkaloids 
isolated from the plant, have been shown to have activity against 
Plasmodium falciparum both in vitro and in vivo as earlier reported [6-
8]. The root of the plant also contains glycosides. Cardiac glycosides 
treat heart problems that may result from severe malaria attack. 
Phytochemicals are non-nutritive plant chemicals that have 
protective or disease preventive properties. Plants produce these 
chemicals substances to protect themselves, and they also protect 
humans against certain diseases [23]. 
Table 2: Phytochemical constituents of C. sanguinolenta roots 
extract 











Fats and oils - 
Acid compounds - 
Terpenoids +++ 
Key: +++ High concentration, ++ moderate concentration, - absent
 
Table 3: Properties of C. sanguinolenta root extract tablets. 
Batch Weight (mg ± CV)*  Hardness  
(kgf ± SD)a  
Disintegration time (min ± SD)a  Friability (%)*  
F1(2 % gelatin)   311.15 ± 1.76   4.76 ± 0.05 8.00 ± 0.10 1.28 
F2 (4 % gelatin)  310.95 ± 2.42  5.80 ± 0.07 13.50 ± 0.21 0.84 
G1 (2 % SCMC)  303.90 ± 2.60  2.00 ± 0.03 10.00 ± 0.17  1.07 
G2(4 % SCMC)  294.55 ± 1.65 3.06 ± 0.03 18.60 ± 0.11 1.31 
G3 (6 % SCMC)  296.30 ± 1.31  4.18 ± 0.10 20.10 ± 0.23 1.04 
G4 (8 % SCMC)  296.00 ± 1.78 5.00 ± 0.07 31.00 ± 0.27 0.92 
*Mean for 20 tablets, aMean for 10 tablets ± SD, CV: coefficient of variation, SD: standard deviation, F1 and F2 contain 2 and 4 %w/w 
gelatin, G1 – G4 contain 2, 4, 6, and 8 %w/w SCMC; SCMC: sodium carboxymethyl cellulose, P < 0.05 was considered significant.
 
Tablet properties 
The results of the properties of C. sanguinolenta root extract tablets 
are presented in Table 3. From the results, all the batches of C. 
sanguinolenta tablets formulated with different binders and varying 
binder concentration passed the uniformity of weight test and 
deviations obtained complied with BP standards of not more than 5 
% for tablets weighing 250 mg or more [21].  
The results of disintegration time test of tablets presented in Table 3 
showed that tablets formulated with 2 and 4 % of gelatin (F1 and 
F2) and 2 % SCMC (G1) complied with BP specifications for normal 
release tablets with disintegration time of < 15 min. However, 
tablets formulated with 4, 6, and 8 % SCMC (G2, G3 and G4) 
respectively failed the tablets disintegration time tests with 
disintegration times that were significantly above 15 min (p < 0.05). 
Therefore, the disintegration time of the tablet formulations was 
significantly affected by the type of binder and concentration used 
during formulation (p < 0.05). Disintegration time of tablets 
increased as the concentration of the binder increased as shown in 
Table 3.  
The hardness of the tablet formulations was significantly affected by 
the type of binder and concentration (p < 0.05). C. sanguinolenta 
tablets formulated gelatin significantly showed higher hardness 
values than SCMC (p < 0.05). Tablets hardness also increased as the 
concentration of the binder increased as shown in Table 3. Tablets 
formulated with 2 and 4 % gelatin (F1 and F2) complied with BP 
specifications for tablets hardness with values of ≥ 5 kgf. However, 
tablets formulated with 2, 4, and 6 % SCMC (G1, G2 and G3) failed  
 
the test for tablets hardness with values < 5 kgf, while tablets 
formulated   with 8 %   (G4)   passed   the hardness test as shown in 
Table 3. However, tablet hardness may be a function of formulation 
excipient, physical properties of the granules and compression 
pressure [24]. 
Tablets friability results presented in Table 3 showed that C. 
sanguinolenta tablets formulated gelatin and SCMC complied with 
BP specifications for tablets prepared by wet granulation method 
with percent friability of approximately ≤ 1 %. Therefore, the tablets 
could withstand handling, packaging and transportation without 
compromising the properties of the tablets.  
CONCLUSION 
Cryptolepis sanguinolenta root extract tablets were produced by wet 
granulation method using gelatin and SCMC respectively as binders. 
The properties of the tablets were affected by the binder type and 
concentration of the binder used in formulating the tablets. Increase 
in binder concentration caused an increase in hardness and 
disintegration time of tablets. The results obtained from the study 
showed that gelatin showed good properties for formulating 
Cryptolepis sanguinolenta normal release tablets than SCMC. 
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